Achilles Therapeutics plc (NASDAQ:ACHL) Sees Significant Drop in Short Interest

Achilles Therapeutics plc (NASDAQ:ACHL) was the target of a large decline in short interest in the month of February. As of February 28th, there was short interest totalling 478,300 shares, a decline of 40.1% from the February 13th total of 797,900 shares. Approximately 1.3% of the shares of the company are sold short. Based on an average daily volume of 1,070,000 shares, the days-to-cover ratio is presently 0.4 days.

Achilles Therapeutics Trading Up 0.7 %

ACHL opened at $1.43 on Friday. Achilles Therapeutics has a 12-month low of $0.63 and a 12-month high of $1.44. The company has a market cap of $58.77 million, a price-to-earnings ratio of -0.87 and a beta of 1.25. The company’s 50 day moving average is $1.29 and its 200 day moving average is $1.09.

Institutional Investors Weigh In On Achilles Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets bought a new stake in Achilles Therapeutics during the fourth quarter valued at about $57,000. Two Sigma Investments LP lifted its position in shares of Achilles Therapeutics by 190.1% during the 4th quarter. Two Sigma Investments LP now owns 61,637 shares of the company’s stock valued at $70,000 after buying an additional 40,388 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Achilles Therapeutics during the 4th quarter valued at approximately $31,000. Finally, Two Sigma Advisers LP raised its stake in Achilles Therapeutics by 52.7% during the 4th quarter. Two Sigma Advisers LP now owns 34,200 shares of the company’s stock worth $39,000 after acquiring an additional 11,800 shares during the period. 56.38% of the stock is currently owned by hedge funds and other institutional investors.

Achilles Therapeutics Company Profile

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.